JP2010540453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540453A5 JP2010540453A5 JP2010526011A JP2010526011A JP2010540453A5 JP 2010540453 A5 JP2010540453 A5 JP 2010540453A5 JP 2010526011 A JP2010526011 A JP 2010526011A JP 2010526011 A JP2010526011 A JP 2010526011A JP 2010540453 A5 JP2010540453 A5 JP 2010540453A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- targeting moiety
- interferon
- linker comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 25
- 230000008685 targeting Effects 0.000 claims 10
- 102000014150 Interferons Human genes 0.000 claims 8
- 108010050904 Interferons Proteins 0.000 claims 8
- 229940079322 interferon Drugs 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 239000000439 tumor marker Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99471707P | 2007-09-21 | 2007-09-21 | |
| US60/994,717 | 2007-09-21 | ||
| PCT/US2008/077074 WO2009039409A1 (en) | 2007-09-21 | 2008-09-19 | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014154820A Division JP6087871B2 (ja) | 2007-09-21 | 2014-07-30 | ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540453A JP2010540453A (ja) | 2010-12-24 |
| JP2010540453A5 true JP2010540453A5 (enExample) | 2011-11-10 |
| JP5591701B2 JP5591701B2 (ja) | 2014-09-17 |
Family
ID=40468388
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010526011A Active JP5591701B2 (ja) | 2007-09-21 | 2008-09-19 | 強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン |
| JP2014154820A Expired - Fee Related JP6087871B2 (ja) | 2007-09-21 | 2014-07-30 | ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す |
| JP2016215048A Pending JP2017031215A (ja) | 2007-09-21 | 2016-11-02 | ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014154820A Expired - Fee Related JP6087871B2 (ja) | 2007-09-21 | 2014-07-30 | ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す |
| JP2016215048A Pending JP2017031215A (ja) | 2007-09-21 | 2016-11-02 | ターゲティング化インターフェロンは強力なアポトーシス活性および抗腫瘍活性を示す |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9139634B2 (enExample) |
| EP (3) | EP3150218B1 (enExample) |
| JP (3) | JP5591701B2 (enExample) |
| KR (2) | KR101759460B1 (enExample) |
| CN (3) | CN101868246A (enExample) |
| AU (1) | AU2008302111B2 (enExample) |
| BR (1) | BRPI0817108B8 (enExample) |
| CA (1) | CA2699944C (enExample) |
| ES (1) | ES2536772T3 (enExample) |
| IL (2) | IL204644A (enExample) |
| MX (2) | MX349306B (enExample) |
| WO (1) | WO2009039409A1 (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103897063B (zh) | 2007-06-01 | 2017-04-12 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| CN102770458A (zh) * | 2009-12-02 | 2012-11-07 | 阿塞勒隆制药公司 | 用于增加Fc融合蛋白的血清半寿期的组合物和方法 |
| ES2611479T3 (es) * | 2010-06-16 | 2017-05-09 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Anticuerpos contra endoplasmina y su uso |
| EP3543257A1 (en) | 2010-07-28 | 2019-09-25 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| CA2858350A1 (en) | 2011-01-14 | 2013-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| EP2718328A4 (en) * | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM |
| WO2013059885A2 (en) * | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| US8961971B2 (en) | 2011-12-22 | 2015-02-24 | Development Center For Biotechnology | Bispecific T-cell activator antibody |
| AU2013211059B8 (en) | 2012-01-20 | 2017-12-21 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted mutant alpha-helical bundle cytokines |
| CA2866126A1 (en) * | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| WO2013164694A1 (en) * | 2012-04-30 | 2013-11-07 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| SG10202006507XA (en) | 2012-05-30 | 2020-08-28 | Chugai Pharmaceutical Co Ltd | Target-tissue-specific antigen-binding molecule |
| CN103505722B (zh) * | 2012-06-19 | 2016-04-13 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法 |
| WO2014028502A1 (en) * | 2012-08-13 | 2014-02-20 | ImmunGene Inc. | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
| KR20150058236A (ko) * | 2012-08-20 | 2015-05-28 | 글리크닉 인코포레이티드 | 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자 |
| WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| PL2970512T3 (pl) | 2013-03-12 | 2019-03-29 | Biocon Limited | Immunomodulujące białka fuzyjne i sposoby ich otrzymywania |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| US10093745B2 (en) | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
| EP3019533B1 (en) * | 2013-07-11 | 2020-01-08 | The Scripps Research Institute | Coiled coil immunoglobulin fusion proteins and compositions thereof |
| MX375441B (es) | 2013-07-18 | 2025-03-06 | Vib Vzw | Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor. |
| AU2014291961B2 (en) | 2013-07-19 | 2018-09-27 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted modified TNF family members |
| US9732135B2 (en) * | 2013-07-19 | 2017-08-15 | Vib Vzw | Targeting of human interferon antagonists |
| DK3022226T3 (en) | 2013-07-19 | 2019-03-25 | Vib Vzw | TARGETED MODIFIED IL-1 FAMILY MEMBERS |
| AU2014306322A1 (en) * | 2013-08-09 | 2016-03-17 | The Trustees Of The University Of Pennsylvania | Combination of IFN-gamma with anti-erbB antibody for the treatment of cancers |
| US11446516B2 (en) | 2013-08-09 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Methods of increasing response to cancer radiation therapy |
| CN104193828B (zh) * | 2013-09-12 | 2017-04-05 | 北京韩美药品有限公司 | 同时阻断her2和vegfr信号通路的重组融合蛋白 |
| CN105829349B (zh) * | 2013-10-15 | 2023-02-03 | 斯克利普斯研究所 | 肽嵌合抗原受体t细胞开关和其用途 |
| CN103536917B (zh) * | 2013-10-30 | 2015-03-11 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗肿瘤中的用途及相关的产品和方法 |
| AU2014358191B2 (en) | 2013-12-04 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
| US10308697B2 (en) | 2014-04-30 | 2019-06-04 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| UA125637C2 (uk) | 2014-10-29 | 2022-05-11 | Тева Фармасьютікалз Острейліа Пті Лтд | ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b |
| EP3221351B1 (en) * | 2014-11-19 | 2024-11-13 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for cancer treating conditions relating to over expressions of epha2 |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| US20170002057A1 (en) * | 2015-02-26 | 2017-01-05 | Nal Pharmaceutical Group Limited | Compositions containing fusion protein of albumin and analogs thereof, methods for making and using the same |
| KR101838919B1 (ko) | 2015-03-03 | 2018-03-15 | 에이비온 주식회사 | 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법 |
| US20210009720A1 (en) * | 2015-03-03 | 2021-01-14 | Genopharm Inc. | Human interferon-beta variant conjugated immunocytokine and method for preparing same |
| WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
| EP3283113A4 (en) | 2015-04-15 | 2018-12-05 | The California Institute for Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
| WO2016201251A1 (en) * | 2015-06-12 | 2016-12-15 | Immungene, Inc. | Focused interferon immunotherapy for treatment of cancer |
| SI3325011T1 (sl) | 2015-07-24 | 2021-02-26 | Gliknik Inc. | Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa |
| JP6452577B2 (ja) * | 2015-08-27 | 2019-01-16 | 株式会社沖データ | 画像形成装置 |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| EP3402509A4 (en) * | 2016-01-14 | 2019-07-10 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | TUMOR SPECIFIC IFNA SECRETION BY CAR T CELLS FOR RESTORING SOLID TUMOR MICRO ENVIRONMENT |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| EP4276114A3 (en) | 2016-03-07 | 2024-02-21 | Vib Vzw | Cd20 binding single domain antibodies |
| WO2017180764A1 (en) * | 2016-04-12 | 2017-10-19 | Immungene, Inc. | Focused interferon immunotherapy |
| US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| CA3026420A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
| US11618784B2 (en) | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
| KR102613430B1 (ko) | 2016-10-19 | 2023-12-18 | 더 스크립스 리서치 인스티튜트 | 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도 |
| JP7204643B2 (ja) | 2016-10-24 | 2023-01-16 | オリオニス バイオサイエンシズ ビーブイ | 標的変異インターフェロン－ガンマおよびその使用 |
| IL266988B2 (en) | 2016-12-09 | 2024-11-01 | Gliknik Inc | Methods of treating inflammatory disorders with multivalent fc compounds |
| EP3551647A4 (en) | 2016-12-09 | 2021-01-13 | Gliknik Inc. | MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER |
| RU2766582C2 (ru) | 2016-12-23 | 2022-03-15 | Ремд Биотерапьютикс, Инк. | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| WO2018146074A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| BR112020002706A2 (pt) | 2017-08-09 | 2020-08-25 | Orionis Biosciences Inc. | agentes de ligação a clec9a e uso dos mesmos |
| WO2019032661A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | CD8 LIAISON AGENTS |
| WO2019051204A1 (en) | 2017-09-08 | 2019-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER |
| US12415843B2 (en) | 2018-03-19 | 2025-09-16 | The Regents Of The University Of California | Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| IL317002A (en) | 2018-08-10 | 2025-01-01 | Chugai Pharmaceutical Co Ltd | Anti-CD137 antigen binding molecule and use thereof |
| CA3118892A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| CN121652287A (zh) * | 2019-03-06 | 2026-03-13 | 德卡生物科学公司 | Il-10变体分子和治疗炎性疾病和肿瘤的方法 |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| AU2020258384B2 (en) | 2019-04-15 | 2026-05-14 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer |
| US12544426B2 (en) | 2019-06-19 | 2026-02-10 | Orionis Biosciences, Inc. | Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes |
| KR20210021861A (ko) * | 2019-08-19 | 2021-03-02 | (주)제노팜 | 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법 |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| EP4069291A1 (en) | 2019-12-03 | 2022-10-12 | Evotec International GmbH | Interferon-associated antigen binding proteins and uses thereof |
| EP4142786A4 (en) * | 2020-04-27 | 2024-06-19 | Ohio State Innovation Foundation | LIVE ATTENUATED MEASLES VIRUS VACCINE AGAINST SARS-COV-2 |
| EP4181957A4 (en) | 2020-07-20 | 2024-08-07 | Deka Biosciences, Inc. | TWO-CYTOKINE FUSION PROTEIN COMPRISING IL-10 |
| CA3228311A1 (en) * | 2021-08-12 | 2023-02-16 | Ke HE | Bispecific recombinant protein and use thereof |
| KR20240015035A (ko) * | 2022-07-25 | 2024-02-02 | 충남대학교산학협력단 | 클로로톡신의 분비를 위한 재조합 발현 벡터 및 이로형질전환된 약독화 살모넬라 균주 |
| WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| US20240376229A1 (en) | 2023-05-12 | 2024-11-14 | Regeneron Pharmaceuticals, Inc. | Interferon receptor antagonists and uses thereof |
| WO2025106883A1 (en) * | 2023-11-15 | 2025-05-22 | President And Fellows Of Harvard College | Engineered fc-prolactin fusions to increase lactation |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4589071A (en) | 1982-04-19 | 1986-05-13 | Nissan Motor Co., Ltd. | Method and apparatus for controlling reduction ratio of continuously variable transmission with acceleration compensation |
| US4545985A (en) | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
| US4894443A (en) | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| EP0188256B1 (en) | 1985-01-14 | 1991-08-21 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5976531A (en) | 1990-04-19 | 1999-11-02 | The Dow Chemical Company | Composite antibodies of human subgroup IV light chain capable of binding to tag-72 |
| SK281143B6 (sk) | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| ES2191702T3 (es) | 1994-03-17 | 2003-09-16 | Merck Patent Gmbh | Fv monocatenarios anti-egfr y anticuerpos anti-egfr. |
| ES2167391T3 (es) | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | Inmunoconjugados ii. |
| US6428788B1 (en) | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
| DE69638269D1 (de) | 1995-06-14 | 2010-11-18 | Univ California | Hochaffine humane antikörper gegen tumorantigene |
| ATE247488T1 (de) * | 1995-10-13 | 2003-09-15 | Us Gov Health & Human Serv | Immunotoxin enthaltend ein disulfid- stabilisiertes antikörperfragment |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| BR9707589A (pt) * | 1996-02-20 | 2000-01-04 | Applied Research Systems | Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular. |
| US6645490B2 (en) * | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| CA2345817C (en) | 1998-10-05 | 2013-02-12 | M&E Biotech A/S | Novel methods for therapeutic vaccination |
| CN100480266C (zh) | 1998-10-16 | 2009-04-22 | 拜奥根Idec马萨诸塞公司 | 干扰素-β融合蛋白及用途 |
| ATE407697T1 (de) * | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| EP1274720A4 (en) * | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| AU6541801A (en) * | 2000-06-22 | 2002-01-02 | Idec Pharma Corp | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
| US7183388B2 (en) | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
| US20020193569A1 (en) | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| RU2004127458A (ru) | 2002-02-14 | 2005-10-27 | Иммуномедикс, Инк. (Us) | Анти-cd20 антитела, их гибридные белки и способы их использования |
| US7736652B2 (en) | 2002-03-21 | 2010-06-15 | The Regents Of The University Of California | Antibody fusion proteins: effective adjuvants of protein vaccination |
| US20070003514A1 (en) | 2002-04-05 | 2007-01-04 | The Regents Of The University Of California | Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| JP2004093527A (ja) * | 2002-09-04 | 2004-03-25 | Center For Advanced Science & Technology Incubation Ltd | 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法 |
| EP1594965A2 (en) * | 2003-02-18 | 2005-11-16 | MERCK PATENT GmbH | Fusion proteins of interferon alpha muteins with improved properties |
| WO2005021710A2 (en) * | 2003-06-02 | 2005-03-10 | University Of Miami | Chimeric molecules and methods of use |
| US20050232931A1 (en) * | 2003-06-13 | 2005-10-20 | Oncomax Acquisition Corp. | Preparation and application of anti-tumor bifunctional fusion proteins |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| EP3342782B1 (en) * | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
| KR20090006221A (ko) * | 2004-07-26 | 2009-01-14 | 아스테리온 리미티드 | 연결체들 |
| CA2593648A1 (en) | 2005-01-10 | 2006-07-13 | Research Development Foundation | Targeted chimeric molecules for cancer therapy |
| US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
| CA2604032C (en) * | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| MX2007014889A (es) * | 2005-05-26 | 2008-02-19 | Schering Corp | Fusion de interferon-inmunoglobulina g. |
| JP5208733B2 (ja) * | 2005-06-29 | 2013-06-12 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 組換えインターフェロンα２（ＩＦＮα２）変異体 |
| NZ542111A (en) * | 2005-08-30 | 2008-04-30 | Otago Innovation Ltd | Novel assay |
| JP4860703B2 (ja) | 2005-10-06 | 2012-01-25 | ゼンコー・インコーポレイテッド | 最適化された抗ｃｄ３０抗体 |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| US20100047164A1 (en) | 2008-04-11 | 2010-02-25 | Duke University | Anti-Tumor Antibodies |
| WO2009134870A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
| WO2010033866A2 (en) | 2008-09-19 | 2010-03-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma |
| BRPI1013990A2 (pt) | 2009-05-06 | 2019-04-30 | Biotest Ag | método para tratar uma doença , e, combinação anticâncer |
| US20110165122A1 (en) | 2009-11-10 | 2011-07-07 | The Regents Of The University Of California | Method for targeted and sustained antiviral therapy |
| WO2012075324A1 (en) | 2010-12-02 | 2012-06-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating a tumor using an antibody that specifically binds hmw-maa |
| RU2013139267A (ru) | 2011-02-10 | 2015-03-20 | Рош Гликарт Аг | Улучшенная иммунотерапия |
| EP2764025B1 (en) | 2011-10-04 | 2017-11-29 | IGEM Therapeutics Limited | Ige-antibodies against hmw-maa |
| CA2866126A1 (en) * | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| US10093745B2 (en) | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
-
2008
- 2008-09-19 CN CN200880117225A patent/CN101868246A/zh active Pending
- 2008-09-19 KR KR1020167014105A patent/KR101759460B1/ko not_active Expired - Fee Related
- 2008-09-19 MX MX2014010567A patent/MX349306B/es unknown
- 2008-09-19 CN CN201410160383.9A patent/CN103880965B/zh active Active
- 2008-09-19 US US12/678,981 patent/US9139634B2/en active Active
- 2008-09-19 CN CN201810058393.XA patent/CN108129573B/zh active Active
- 2008-09-19 JP JP2010526011A patent/JP5591701B2/ja active Active
- 2008-09-19 MX MX2010003099A patent/MX2010003099A/es active IP Right Grant
- 2008-09-19 AU AU2008302111A patent/AU2008302111B2/en not_active Ceased
- 2008-09-19 EP EP16195608.1A patent/EP3150218B1/en active Active
- 2008-09-19 ES ES08831632.8T patent/ES2536772T3/es active Active
- 2008-09-19 EP EP20080831632 patent/EP2200634B1/en active Active
- 2008-09-19 EP EP14180412.0A patent/EP2853267B1/en active Active
- 2008-09-19 KR KR1020107008737A patent/KR101661770B1/ko active Active
- 2008-09-19 BR BRPI0817108A patent/BRPI0817108B8/pt active IP Right Grant
- 2008-09-19 WO PCT/US2008/077074 patent/WO2009039409A1/en not_active Ceased
- 2008-09-19 CA CA2699944A patent/CA2699944C/en active Active
-
2009
- 2009-12-30 US US12/650,329 patent/US8258263B2/en active Active
-
2010
- 2010-03-21 IL IL20464410A patent/IL204644A/en active IP Right Grant
-
2011
- 2011-01-05 US US12/985,122 patent/US8563692B2/en not_active Expired - Fee Related
-
2013
- 2013-08-30 US US14/015,838 patent/US9534033B2/en active Active
-
2014
- 2014-06-22 IL IL233305A patent/IL233305B/en active IP Right Grant
- 2014-07-30 JP JP2014154820A patent/JP6087871B2/ja not_active Expired - Fee Related
-
2016
- 2016-11-02 JP JP2016215048A patent/JP2017031215A/ja active Pending
- 2016-11-22 US US15/359,456 patent/US10182984B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2752248T3 (es) | Heterodímero proteínico y uso del mismo | |
| JP2021524270A5 (enExample) | ||
| WO2012094653A4 (en) | Compositions and methods for macromolecular drug delivery | |
| JP2021524275A5 (enExample) | ||
| NZ591130A (en) | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof | |
| JP2010516290A5 (enExample) | ||
| JP2012100677A5 (enExample) | ||
| JP2010516708A5 (enExample) | ||
| CN105142663A (zh) | 用于癌症靶向治疗的含有结合白蛋白的精氨酸脱亚胺酶的药物组合物 | |
| CN110981958B (zh) | 一种pd-l1抗体 | |
| JP2018512124A5 (enExample) | ||
| JP2009540852A5 (enExample) | ||
| JP7330517B2 (ja) | 異種タンパク質産生のための人工分泌ペプチド | |
| JP2020509737A5 (enExample) | ||
| CN110300766A (zh) | 新型重组双功能融合蛋白及其制备方法和用途 | |
| CN105111314A (zh) | 一种新型融合蛋白、药物组合物及其制备方法和用途 | |
| JP2021517472A (ja) | 抗ｐｄ−ｌ１ワクチン組成物 | |
| CN117940461A (zh) | 一种双特异性抗体及其用途 | |
| CN111218443B (zh) | 合成核酸药物偶联物的方法 | |
| CN101143902B (zh) | 抗HER2单链抗体-力达霉素强化融合蛋白HER2(Fv-LDM) | |
| JP2006345867A5 (enExample) | ||
| CN115028738B (zh) | 一种Fc融合蛋白双重靶向降解剂及应用 | |
| JP2024536791A5 (enExample) | ||
| JP7239987B2 (ja) | 薬物送達のための抗体融合タンパク質 | |
| JP2015533372A5 (enExample) |